Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
GS.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FY.5.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FE.1.1.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.20NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FY.3.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.3.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.24NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.3.20NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.5.2.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-22381.5US
HK.27NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.30NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.5.1.17NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DV.6.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FK.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
GY.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBC.1.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FY.4.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HH.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GY.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FY.5.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HH.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.85NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FU.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.86NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.41.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-25520.9US
GS.4.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JF.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.5.1.13NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JG.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.28NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBBNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.13NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FU.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBL.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.24.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FY.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.3.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.9.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FE.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.13NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FR.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FY.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FY.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.3.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FE.1.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FY.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used